Cariprazine augmentation in patients with treatment resistant unipolar depression who failed to respond to previous atypical antipsychotic add-on. A case-series
Among individuals receiving an adequate pharmacological treatment for Major Depressive Disorder (MDD), only 30% reach a full symptom recovery; the remaining 70% will experience either a pharmacological response without remission or no response at all thus configuring treatment resistant depression (...
Main Authors: | Enrico Pessina, Azzurra Martini, Fabiola Raffone, Vassilis Martiadis |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-11-01
|
Series: | Frontiers in Psychiatry |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1299368/full |
Similar Items
-
Switching Clozapine to Cariprazine in Three Patients with Persistent Symptoms of Schizophrenia: A Case Series
by: Duque-Yemail JD, et al.
Published: (2022-07-01) -
A review on the pharmacology of cariprazine and its role in the treatment of negative symptoms of schizophrenia
by: Panneer Selvan, et al.
Published: (2024-04-01) -
Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies
by: Barabássy Á, et al.
Published: (2021-04-01) -
Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms
by: Octavian Vasiliu
Published: (2021-11-01) -
Dosing Cariprazine Within and Beyond Clinical Trials: Recommendations for the Treatment of Schizophrenia
by: Elmars Rancans, et al.
Published: (2022-01-01)